EGFR and non-small cell lung carcinoma: In addition, detecting somatic mutations of exons 19 and 21 in EGFR may provide prognostic information for patients with advanced NSCLC.[8,9] Therefore, the EGFR mutation is both a prognostic factor and a predictive factor for the response of TKI targeting therapy.